{
    "title": "106_s2501",
    "content": "The \"Generic Pharmaceutical Access and Choice for Consumers Act of 2000\" includes provisions for encouraging the use of generic drugs in various healthcare programs, ensuring therapeutic equivalence of generic drugs, and promoting the preference for generic pharmaceuticals under the Medicare program. SEC. 2. FINDINGS AND PURPOSES. Generic pharmaceuticals approved by the FDA are therapeutically equivalent to brand-name drugs, providing a safe and cost-effective alternative. The market has become more competitive due to the availability of generics, saving purchasers billions annually and offering significant cost savings on prescriptions. The Act aims to reduce prescription drug costs for the government and beneficiaries by promoting the use of generic drugs over brand-name ones. Generic pharmaceuticals have gained popularity, with their market share doubling in the last decade. The FDA is required to determine the therapeutic equivalence of generic drugs to their brand-name counterparts. TITLE I--ENCOURAGEMENT OF THE USE OF GENERIC DRUGS\n\nSEC. 101. ENCOURAGEMENT OF THE USE OF GENERIC DRUGS UNDER THE PUBLIC HEALTH SERVICE ACT. Part B of title II of the Public Health Service Act is amended to include a new section encouraging the use of generic drugs. The provision of health care items or services under this Act must prioritize generic drug prescriptions, unless specifically ordered by the provider or requested by the individual. Generic drugs are those approved as therapeutic equivalents by the Secretary, while nongeneric drugs are approved under a different section of the Federal Food, Drug, and Cosmetic Act. The amendment made by this section (505(b) of the Federal Food, Drug, and Cosmetic Act) shall apply to any drug furnished on or after the enactment date of this Act. SEC. 102 amends Section 8902 of title 5, United States Code, to require carriers in the Federal Employees Health Benefits Program to provide, pay, or reimburse the cost of generic drugs unless the nongeneric form is specifically ordered by the provider or requested by the individual. The amendment applies to drugs furnished during contract years beginning on or after January 1, 2001. The Social Security Act is amended to define drugs as generic unless specifically ordered by the provider or requested by the individual. This amendment applies to drugs furnished on or after the date of enactment, except for Medicare+Choice plans which apply starting January 1, 2001. SEC. 104 amends the Social Security Act to require states to use generic drugs unless specifically ordered by the provider or requested by the individual. This applies to drugs furnished under approved or renewed State plans. SEC. 105 amends the Indian Health Care Improvement Act to encourage the use of generic drugs by the Indian Health Service when providing health care items or services. The amendment specifies conditions under which non-generic drugs may be used. The effective date of this amendment is upon the enactment of the Act. SEC. 106 amends title 38 of the United States Code to encourage the use of generic drugs when furnishing prescription drugs under veterans programs. The Secretary must provide a generic form of the drug unless specifically ordered by the provider or requested by the individual. Effective date applies to drugs furnished after the enactment of this Act. SEC. 107 encourages the use of generic drugs for recipients of uniformed services health care. The Secretary of Defense must ensure that health care providers furnish generic drugs whenever feasible, unless specifically ordered by the prescribing provider or requested by the individual. Effective date applies to drugs furnished after the enactment of this Act. SEC. 108 encourages the use of generic drugs for federal prisoners. The Attorney General must ensure that health care providers furnish generic drugs whenever feasible, unless specifically ordered by the prescribing provider or requested by the prisoner. Effective date applies to drugs furnished after the enactment of this Act. The amendment to Section 505(j) of the Federal Food, Drug, and Cosmetic Act requires the Secretary to determine if a new drug is therapeutically equivalent to a listed drug before approving an abbreviated application. Therapeutic equivalence is based on factors such as active ingredients, dosage form, route of administration, strength, and standards. The amendment to Section 505(j) of the Federal Food, Drug, and Cosmetic Act requires the Secretary to determine therapeutic equivalence of a new drug before approving an abbreviated application. This includes factors like active ingredients, dosage form, route of administration, strength, and standards. The new drug must have the same clinical effect and safety profile as the listed drug, and meet bioequivalence standards. State laws on therapeutic equivalence are superseded by this provision. The Secretary must update a list of therapeutically equivalent drugs every 30 days. The amendments made by this section shall take effect on the date of enactment of this Act. TITLE III--GENERIC PHARMACEUTICALS AND MEDICARE REFORM\n\nSENSE OF THE SENATE REGARDING A PREFERENCE FOR THE USE OF GENERIC PHARMACEUTICALS UNDER THE MEDICARE PROGRAM: The Senate believes that legislation should prioritize the safe and cost-effective use of generic pharmaceuticals when adding a prescription drug benefit to the Medicare program."
}